Trial · NCT01860807

Trial of Ibudilast for Methamphetamine Dependence

NCT01860807, Phase 2, Completed, University of California, Los Angeles; results first posted 2019-01-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Trial of Ibudilast for Methamphetamine Dependence. Trials, record NCT01860807. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01860807

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Trial of Ibudilast for Methamphetamine Dependence
NCT number: NCT01860807
Status: Completed
Phases: Phase 2
Enrollment: 125 participants, actual
Lead sponsor: University of California, Los Angeles
Conditions: Methamphetamine Dependence, HIV Infection
Interventions: Ibudilast, Placebo
First posted: 2013-05-23
Last updated: 2019-01-30
Results first posted: 2019-01-30
Limitations and caveats: Study did not determine if ibudilast may help patients who have stopped methamphetamine use prior to starting medication

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Methamphetamine Use	12 weeks	End of treatment methamphetamine abstinence

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Methamphetamine Use	12 weeks		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Methamphetamine Use	Ibudilast		9		Participants
Methamphetamine Use	Placebo		10		Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Ibudilast	64
Overall Study	STARTED	Placebo	61
Overall Study	COMPLETED	Ibudilast	34
Overall Study	COMPLETED	Placebo	32
Overall Study	NOT COMPLETED	Ibudilast	30
Overall Study	NOT COMPLETED	Placebo	29

Source ClinicalTrials.gov

Adverse events14

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Headache	Nervous system disorders	Ibudilast	32	64
other	Headache	Nervous system disorders	Placebo	11	61
other	Nausea	Gastrointestinal disorders	Ibudilast	11	64
other	Nausea	Gastrointestinal disorders	Placebo	9	61
other	Insomnia	Psychiatric disorders	Ibudilast	10	64
other	Insomnia	Psychiatric disorders	Placebo	5	61
other	Diarrhea	Gastrointestinal disorders	Ibudilast	8	64
other	Diarrhea	Gastrointestinal disorders	Placebo	7	61
serious	Convulsion	Nervous system disorders	Ibudilast	1	64	1
serious	Convulsion	Nervous system disorders	Placebo	0	61	0

1 to 10 of 14Source ClinicalTrials.gov

See all 14 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Ibudilast	0	64
Total, all-cause mortality	Placebo	0	61
Total, other adverse events	Ibudilast	57	64
Total, other adverse events	Placebo	32	61
Total, serious adverse events	Ibudilast	2	64
Total, serious adverse events	Placebo	1	61

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
R01DA035054	Randomized Trial of Ibudilast for Methamphetamine Dependence	HEINZERLING, KEITH GREGORY	UNIVERSITY OF CALIFORNIA LOS ANGELES	NATIONAL INSTITUTE ON DRUG ABUSE	2012 to 2017

Source NIH RePORTER

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Ibudilast vs Placebo: Methamphetamine Use	Trial comparisons
Ibudilast vs Placebo: deaths from any cause	Trial comparisons
Ibudilast vs Placebo: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01860807

GET https://conductscience.org/api/trials/v1/NCT01860807/registered

API reference For AI assistants